Drugs / sIPV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03032588 | Oct 2017 → May 2018 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sIPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03032588 ↗ |
| Modality | Vaccine | “Participants will receive single intramuscular injection of the trivalent inactivated poliovirus vaccine based on Sabin strains produced on PER.C6 cells (sIPV) on Day 1.” NCT03032588 ↗ |
| Route | Intramuscular | “Participants will receive single intramuscular injection of the trivalent inactivated poliovirus vaccine based on Sabin strains produced on PER.C6 cells (sIPV) on Day 1.” NCT03032588 ↗ |